17,800 Shares in Pulse Biosciences, Inc $PLSE Purchased by Strs Ohio

Key Points

• Strs Ohio acquired 17,800 shares of Pulse Biosciences, valued at approximately $286,000, as part of its new position reported in a 13F filing with the SEC.
• Insider transactions include CTO Darrin Uecker selling 25,000 shares worth $394,250 while Director Robert W. Duggan purchased 34,659 shares valued at approximately $508,100.
• Pulse Biosciences received an "outperform" rating with a price target of $22.00 from Oppenheimer, reflecting positive analyst sentiment.

Strs Ohio acquired a new position in shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 17,800 shares of the company's stock, valued at approximately $286,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. AlphaQuest LLC increased its position in Pulse Biosciences by 68.0% during the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock worth $50,000 after purchasing an additional 1,261 shares during the last quarter. Rhumbline Advisers increased its position in Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock worth $440,000 after purchasing an additional 1,614 shares during the last quarter. Farther Finance Advisors LLC increased its position in Pulse Biosciences by 24.6% during the first quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock worth $143,000 after purchasing an additional 1,778 shares during the last quarter. Westside Investment Management Inc. increased its position in Pulse Biosciences by 5.5% during the first quarter. Westside Investment Management Inc. now owns 58,155 shares of the company's stock worth $936,000 after purchasing an additional 3,034 shares during the last quarter. Finally, Panoramic Capital LLC increased its position in Pulse Biosciences by 8.5% during the first quarter. Panoramic Capital LLC now owns 52,723 shares of the company's stock worth $848,000 after purchasing an additional 4,152 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, CTO Darrin Uecker sold 25,000 shares of the company's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $15.77, for a total value of $394,250.00. Following the completion of the transaction, the chief technology officer owned 122,872 shares in the company, valued at $1,937,691.44. This represents a 16.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert W. Duggan acquired 34,659 shares of the firm's stock in a transaction on Wednesday, September 10th. The stock was bought at an average price of $14.66 per share, with a total value of $508,100.94. Following the purchase, the director directly owned 47,551,200 shares of the company's stock, valued at $697,100,592. This represents a 0.07% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 90,400 shares of company stock worth $1,465,142 over the last 90 days. Corporate insiders own 74.60% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Oppenheimer initiated coverage on shares of Pulse Biosciences in a research report on Monday, July 7th. They set an "outperform" rating and a $22.00 price target for the company. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $22.00.

Pulse Biosciences Trading Up 0.8%

Shares of Pulse Biosciences stock opened at $17.70 on Wednesday. The company has a fifty day simple moving average of $15.65 and a 200-day simple moving average of $16.15. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -16.86 and a beta of 1.68. Pulse Biosciences, Inc has a 12-month low of $13.77 and a 12-month high of $25.00.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.